Allergan plc. (AGN) Financial Statements (2024 and earlier)

Company Profile

Business Address CLONSHAUGH BUSINESS AND TECHNOLOGY PARK
COOLOCK, DUBLIN, D17 E400
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in millions)

3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 4,5561,9741,7841,9071,210
Cash and cash equivalents 1,2381,6517898801,188
Short-term investments 3,3183229951,02722
Receivables 3,0123,0862,7312,8682,827
Inventory, net of allowances, customer advances and progress billings 1,0831,005943847895
Inventory 1,0831,005943847895
Prepaid expense  519  421 
Asset, held-for-sale, not part of disposal group    46347
Other undisclosed current assets 4242,508786399802
Total current assets: 9,5948,5736,2896,4755,740
Noncurrent Assets
Operating lease, right-of-use asset 478458 
Nontrade receivables  41    
Property, plant and equipment 1,8571,8211,7811,7871,757
Long-term investments and receivables  56  46 
Long-term investments  56  46 
Intangible assets, net (including goodwill) 81,59283,57285,60189,60997,584
Goodwill 42,06642,34143,33745,91349,456
Intangible assets, net (excluding goodwill) 39,52741,23242,26543,69548,127
Regulated entity, other noncurrent assets      93
Other noncurrent assets  130  84 
Other undisclosed noncurrent assets 6611,0574,3653,7871,369
Total noncurrent assets: 84,81586,90891,74795,312100,802
TOTAL ASSETS: 94,40995,48198,036101,788106,543
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 5,6924,9954,6344,7874,696
Accounts payable 471519357350286
Accrued liabilities 5,2214,4774,2784,4374,410
Debt 3,8583,2173,9728681,401
Other undisclosed current liabilities 899124372136
Total current liabilities: 9,6398,3048,8495,7286,232
Noncurrent Liabilities
Long-term debt and lease obligation, including: 19,22320,02419,55422,92922,232
Long-term debt, excluding current maturities 18,78619,60919,554  
Other undisclosed long-term debt and lease obligation     22,92922,232
Liabilities, other than long-term debt 8118216,0406,3845,977
Deferred tax liabilities, net5,2365,5025,225
Other liabilities 811821804882752
Operating lease, liability 437415 
Other undisclosed noncurrent liabilities 6,2386,6352,0331,6161,581
Total noncurrent liabilities: 26,27227,48127,62830,92929,790
Total liabilities: 35,91135,78536,47736,65736,022
Equity
Equity, attributable to parent 58,47559,67561,54265,11470,508
Additional paid in capital 55,88255,81255,74356,51057,203
Accumulated other comprehensive income 1,0411,2821,2161,3451,504
Retained earnings 1,5522,5814,5837,25911,801
Equity, attributable to noncontrolling interest 2321181713
Total equity: 58,49859,69661,56065,13170,521
TOTAL LIABILITIES AND EQUITY: 94,40995,48198,036101,788106,543

Income Statement (P&L) ($ in millions)

3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
Revenues(11,738)4,0514,0903,5974,0803,911
Cost of revenue (641)(782)(498)(6,721)(720)
Cost of goods and services sold (639)(652)(498)(590)(597)
Gross profit: 3,4103,3083,099(2,642)3,191
Operating expenses (4,006)(4,571)(5,414)(2,743)(2,934)
Other undisclosed operating income    5  
Operating income (loss): (597)(1,263)(2,309)(5,384)258
Nonoperating expense (171)(190)(167)(209)(80)
Other nonoperating income (expense) 3(5)14(10)130
Interest and debt expense (194)0(0)671(220)
Loss from continuing operations before equity method investments, income taxes: (961)(1,453)(2,476)(4,922)(43)
Other undisclosed income (loss) from continuing operations before income taxes 194(0)0(671)220
Income (loss) from continuing operations before income taxes: (768)(1,453)(2,476)(5,593)177
Income tax expense (benefit) (18)(302)691,297(213)
Income (loss) from continuing operations: (786)(1,755)(2,407)(4,296)(36)
Income (loss) before gain (loss) on sale of properties: (786)(1,755)(2,407)(4,296)(36)
Net income (loss): (786)(1,755)(2,407)(4,296)(36)
Net loss attributable to noncontrolling interest (1)(4)(1)(4)(2)
Net income (loss) available to common stockholders, diluted: (787)(1,759)(2,408)(4,300)(38)

Comprehensive Income ($ in millions)

3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
Net income (loss): (786)(1,755)(2,407)(4,296)(36)
Other comprehensive income (loss) (241)65(129)(96)(89)
Comprehensive income (loss): (1,026)(1,690)(2,536)(4,392)(125)
Comprehensive loss, net of tax, attributable to noncontrolling interest (1)(4)(1)(4)(2)
Comprehensive income (loss), net of tax, attributable to parent: (1,027)(1,694)(2,537)(4,396)(127)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: